Home
Back to Manufacturing guides

Manufacturing guides

Nutraceutical Contract R&D: Who Owns the Formula

A brand pays for development and receives one page of formula. It runs, until the same formula is moved to a larger batch and comes out darker and softer, because the page never recorded the temperature the syrup was held at. Contract R&D only transfers when the process window travels with the recipe.

A brand pays for twelve weeks of development and receives a one-page formula, a colour reference and a sample jar. It works. Then the brand moves the product to a second plant for a larger batch, and the batch comes out two shades darker and noticeably softer, because the page never said at what temperature the syrup was held or how fast it was cooled.

The formula was never the deliverable. The formula plus the window it runs in is the deliverable, and the window is the part that usually stays behind.

A laboratory bench with roots, a dish of powder and a bottle of oil, the development side of a gummy project.
A laboratory bench with roots, a dish of powder and a bottle of oil, the development side of a gummy project.

What contract R&D actually buys

A dietary supplement and nutraceutical manufacturer selling contract R&D is selling five things, whether or not the proposal says so.

A formula expressed per batch, not per piece, with every ingredient named at the grade it will be bought at. A process description with the parameters that matter and the range each can move in. A specification for the finished product, with methods and limits. A stability protocol, because an unverified shelf life is a guess. And a technical package complete enough for another site to run the same product without calling anyone.

Most proposals price the first two and assume the rest. The rest is what a brand discovers it needs at the worst moment: during a scale-up, an audit, or a retailer's technical review. The production half of the same project is set out in our note on contract manufacturing.

Three clauses that decide ownership

The molecule does not belong to anyone. The right to use the formulation does, and that right is created by wording, not by who paid the invoice.

The first clause is assignment. A development agreement either assigns the resulting formulation to the brand or leaves it with the developer. Both are legitimate; the second is common when the development fee is low or waived, because the plant expects to earn on repeat production. What is not legitimate is ambiguity, which usually surfaces when the brand wants a second source.

The second is background know-how. A plant arrives with prior work: how it deposits a pectin gel, which carrier it uses for a bitter extract, what its curing room does at 22 °C. That know-how predates the project and normally stays with the plant. The clause should say so, and should also say that the brand's formulation does not become the plant's property by being run on its equipment.

The third is improvements. Somebody will change something in year two, usually to fix a problem. Without a clause, the party that made the change can argue it owns the improved version, which is an awkward conversation to have while a batch is on hold.

Why a bench formula does not scale

Development happens in a 5 or 10 litre kettle. Production happens in 500 to 1,000 litre tanks. Four things change with that jump, and all four change the product.

Heat history changes. A small batch heats and cools quickly; a large one holds temperature for longer, and every minute at 90 °C is time an active ingredient spends degrading or a colour spends darkening.

Evaporation changes. A wide shallow kettle loses water faster than a tall tank with a lid, so the same cooking time produces a different solids content. This is why a formula written in percentages of the finished mass has to be recalculated per batch rather than scaled linearly, and why the dosage form changes the arithmetic from the first batch.

Shear changes. A laboratory mixer at 800 rpm and a production agitator at 60 rpm do not put the same stress on a hydrocolloid, and a pectin or gelatin chain that has been mechanically shortened sets differently.

Cooling rate changes. This is the one that catches most projects. A gel network forms over a temperature range, and how long the mass spends in that range decides the final texture. A 5 kg batch that cools in eight minutes and a 500 kg batch that cools in forty produce the same recipe and two different products.

The four numbers to write down

A useful process description carries four measured values, each with a tolerance.

Soluble solids, in degrees Brix, at the point of deposit. It sets sweetness, water activity and the strength of a high-methoxyl pectin gel, which needs roughly 55 per cent or more to set at all.

pH, because it decides both gelation and stability. A pectin gummy typically sits below 3.5; a protein-containing piece usually wants to stay away from the isoelectric point of the protein, which for pea protein is around pH 4.5 to 5.

Water activity, not moisture. A gummy at 0.55 to 0.70 is stable against most mould and yeast growth and still chewy; the same piece at 0.80 will sweat in a jar and lose its shape.

Deposit temperature, and the temperature of the mould at deposit. The gap between them drives how fast the skin forms on the piece, which decides whether it shrinks away from the mould cleanly or sticks.

A formula sheet without these four is not a technical document. It is a recipe card.

Overage is a result, not a habit

Every supplement formula carries more active than the label claims. The size of that excess should come from a stability study, not from caution.

If the twelve-month result at 25 °C and 60 per cent relative humidity is 82 per cent of the initial assay, then to be at 100 per cent of label at month twelve the batch has to start at about 122 per cent. That is a calculated overage with a number behind it. A plant that adds 20 per cent "because it always does" is guessing, and the guess is expensive when the active is a 10:1 extract.

The other side of the same calculation is that overage is not free in sensory terms. More extract means more colour, more bitterness and more powder in a fixed three gram piece, which is why the stability result often decides the flavour brief as well.

The brief that saves a round

A development brief that omits any of six items will come back with a question, and each question is a week.

The dose per serving, and whether the serving is one piece or three. The dosage form, since a gummy, a capsule and a stick pack have different ceilings. The claims the brand intends to use, because a claim can require a dose the format cannot carry, and that is better discovered in week one. The destination market, since permitted ingredients differ. The pack, because the pack decides the stability study. And the shelf life being targeted, because eighteen months and twenty-four months are different development programmes.

The claim point is the one brands most often skip. A formulation developed to hit a 500 mg dose in a three gram gummy is a different project from one developed to hit 250 mg, and a plant that is told only the ingredient will develop the cheaper of the two.

Who owns the assay

A finished product specification cites methods, and methods belong to somebody. An in-house HPLC method is a legitimate way to release a batch, and it is not transferable unless the method is written down and validated in a way another laboratory can repeat.

Two questions settle this at contract stage. Is the method compendial, in-house, or third-party, and if it is in-house, will the full method be handed over? And for a custom supplement formulation manufacturer working with a novel combination, has the method been checked for interference from the other ingredients, or is it a method borrowed from a single-ingredient product?

A method that reads the active correctly in a plain matrix and reads 15 per cent high in a gummy with four other actives is not a quality problem at the plant. It is a specification problem that follows the product for its commercial life.

What to ask for at handover

Five documents, in a form that can be filed rather than discussed.

The batch formula with grades and suppliers or equivalent specifications. The process description with the four measured values and their tolerances. The finished product specification with methods and acceptance limits. The stability protocol and any results generated so far, including the pull points that have not yet been read. And a deviation history from the development batches, which is the document that tells a new site where the process is fragile.

Ask for these before the final invoice, not after. The leverage is in the timing.

Ding Shaohua, Foreign Trade Manager at WANHUACAO, works with brands and distributors on supplement programmes from brief to first shipment, in bulk and in private label, across gummies, capsules, powders and tea. The plant operates under SGS CN23/00007035 for gel confectionery and SC11434160205012 covering eight dosage forms, sports nutrition supplements among them. Reach him on WhatsApp, TikTok, LinkedIn and Facebook.

FAQ

Does the brand own the formula if it paid for development?

Only if the agreement says so. Payment buys the work, not automatically the rights to it. A development contract can assign the formulation to the brand, license it back to the plant for production, or leave ownership with the developer while the brand holds an exclusive licence for its market. Each is workable; the version to avoid is one that does not say which.

Can a formula developed at one plant be moved to another?

Yes, if the technical package is complete. In practice the transfer fails on process parameters rather than ingredients: deposit temperature, cooling rate and solids at deposit are the three that most often go unrecorded. A formula sheet alone usually produces a product that looks right and eats wrong.

How long should development take before the first commercial batch?

It depends on whether stability is included. Bench work and a pilot batch can be weeks; a stability study long enough to support an eighteen-month claim takes months by definition, because the clock cannot be compressed. A programme that promises both a short timeline and a verified shelf life is describing a study that has not been run.

Is contract R&D the same as private label?

No. Private label usually means choosing from an existing catalogue, where the formula is the manufacturer's and several brands may sell the same piece under different labels. Contract R&D produces a formula for one brand, which is why it costs more and why ownership has to be written down.

All News